Last reviewed · How we verify
NCT06734702
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Phase 3 trial testing Neoadjuvant therapy in Neoadjuvant Therapy in 497 participants. Currently enrolling.
29 November 2028
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 497 |
| Start date | 30 November 2024 |
| Primary completion | 29 November 2028 |
| Estimated completion | 29 November 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Neoadjuvant therapy — full drug profile →
- Hypo-RT and concurrent chemotherapy
- CFRT and concurrent chemotherapy
- Consolidative immunotherapy — full drug profile →
Conditions studied
- Neoadjuvant Therapy — all drugs for Neoadjuvant Therapy →
- Concurrent Chemoradiotherapy — all drugs for Concurrent Chemoradiotherapy →
- Immunotherapy — all drugs for Immunotherapy →
- Locally Advanced Non-Small Cell Lung Cancer — all drugs for Locally Advanced Non-Small Cell Lung Cancer →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, any sex, with Neoadjuvant Therapy or Concurrent Chemoradiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Consolidative immunotherapy following concurrent chemoradiotherapy, based on the PACIFIC trial, has become the standard treatment for locally advanced non-small cell lung cancer (LANSCLC), leading to a 5-year survival rate of over 40%. The optimal timing of radiotherapy combined with immunotherapy still requires further exploration. This phase III, randomized controlled clinical trial is to investigate the efficacy and safety of neoadjuvant immuno-chemotherapy followed by concurrent chemoradiotherapy and consolidative immunotherapy, compared with concurrent chemoradiotherapy and consolidative immunotherapy in LANSCLC patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06734702
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neoadjuvant therapy
Trials testing the same drug.
- NCT07103395 — A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade · Phase 2 · recruiting
- NCT06642428 — Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast C · NA · recruiting
- NCT06151379 — Muscle Parameters and Pathological Response in Breast Cancer Patients · completed
- NCT05441098 — Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology · unknown
- NCT05642104 — The Detection of Cell-in-cell Structure (CICs) in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy · unknown
Other recruiting trials for Neoadjuvant Therapy
Currently open trials in the same condition.
- NCT07458529 — Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT07492342 — Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC · Phase 2 · recruiting
- NCT07422974 — Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer · recruiting
- NCT07389629 — Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
- NCT07135856 — Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06734702 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 24 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06734702.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing